Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;40(3):727-738.
doi: 10.1007/s00345-021-03866-4. Epub 2021 Nov 6.

Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results

Jean de la Rosette  1 , Alexey Martov  2 , Rodolfo Hurle  3 , Gabriel Favre  4 , Charalampos Mamoulakis  5 , Manuel Castanheira de Oliveira  6 , Arnulf Stenzl  7 , Estefania Linares-Espinós  8 , Carlos R Trelles Guzmán  8 , Stavros Gravas  9   10 , Thomas Knoll  11 , Mustafa Yucel Boz  12 , Thomas Herrmann  13   14 , Pilar Laguna  12
Affiliations

Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results

Jean de la Rosette et al. World J Urol. 2022 Mar.

Abstract

Purpose: White light (WL) is the traditional imaging modality for transurethral resection of bladder tumour (TURBT). IMAGE1S is a likely addition. We compare 18-mo recurrence rates following TURBT using IMAGE1S versus WL guidance.

Methods: Twelve international centers conducted a single-blinded randomized controlled trial. Patients with primary and recurrent non-muscle-invasive bladder cancer (NMIBC) were randomly assigned 1:1 to TURBT guided by IMAGE1S or WL. Eighteen-month recurrence rates and subanalysis for primary/recurrent and risk groups were planned and compared by chi-square tests and survival analyses.

Results: 689 patients were randomized for WL-assisted (n = 354) or IMAGE1S-assisted (n = 335) TURBT. Of these, 64.7% had a primary tumor, 35.3% a recurrent tumor, and 4.8%, 69.2% and 26.0% a low-, intermediate-, and high-risk tumor, respectively. Overall, 60 and 65 patients, respectively, completed 18-mo follow-up, with recurrence rates of 31.0% and 25.4%, respectively (p = 0.199). In patients with primary, low-/intermediate-risk tumors, recurrence rates at 18-mo were significantly higher in the WL group compared with the IMAGE1S group (31.9% and 22.3%, respectively: p 0.035). Frequency and severity of adverse events were comparable in both treatment groups. Immediate and adjuvant intravesical instillation therapy did not differ between the groups. Potential limitations included lack of uniformity of surgical resection, central pathology review, and missing data.

Conclusion: There was not difference in the overall recurrence rates between IMAGE1S and WL assistance 18-mo after TURBT in patients with NMIBC. However, IMAGE1S-assisted TURBT considerably reduced the likelihood of disease recurrence in primary, low/intermediate risk patients.

Registration: ClinicalTrials.gov Identifier NCT02252549 (30-09-2014).

Keywords: Image 1S imaging; Non-muscle-invasive bladder; Transurethral resection of bladder tumour; Tumour recurrence; White light imaging.

PubMed Disclaimer

References

    1. Fitzmaurice C, Allen C, Barber RM et al (2017) Global, regional, and national cancer incidence, mortality, years of life loss, years lived with disability, and disability adjusted life-years for 32 cancer groups, 1990–2015: a systematic analysis for the Global Burden of Disease Study. JAMA 3:524–548. https://doi.org/10.1001/jamaoncol.2016.5688
    1. Mostafid H, Kamat AM, Daneshmand S et al (2021) Best Practices to optimise quality and outcome of transurethral resection of bladder tumours. Eur Urol Oncol 4:12–19. https://doi.org/10.1016/j.euo.2020.06.010 - PubMed
    1. Babjuk M, Burger M, Comperat EM et al (2019) European Association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma In Situ) - 2019 update. Eur Urol 76:639–657. https://doi.org/10.1016/j.eururo.2019.08.016 - PubMed
    1. Ozono S, Hinotsu S, Tabat S et al (2001) Treated natural history of superficial bladder cancer. Jpn J Clin Oncol 31:536–540. https://doi.org/10.1093/jjco/hye114 - PubMed
    1. Jichlinski P, Leisinger H-J (2005) Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol Int 74:97–101. https://doi.org/10.1159/000083277 - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources